Update in IBD Therapies 2015
Treatment options in inflammatory bowel disease range from mesalamine and budesonide for mild to moderate disease to immuomodulators for patients with refractory disease to the biologic agents for moderate to severe disease. Recent breakthroughs include agents currently FDA-approved for Crohn’s disease or ulcerative colitis as well as those indicated for other inflammatory conditions such as rheumatoid arthritis and psoriasis. Future therapies include novel monoclonal antibodies as well as orally available small molecules.
This presentation was originally recorded at the Best of the Annual Conferences in Digestive Diseases on June 13, 2015 in Rosemont, IL.
Medium: Video with PPT, eLearning
This activity has been designed for gastroenterologist, surgeons, nurses, nurse practitioners, physician assistants, residents, and fellows.
After completing this activity, the participant will demonstrate the ability to:
- Identify currently available FDA-approved therapies for the treatment of Crohn’s disease and ulcerative colitis;
- Identify currently available FDA-approved therapies for other indications that have clinical data in the treatment of IBD;
- Identify novel therapeutic mechanisms in development as potential therapies in IBD.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.